Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael R. Hynes"'
Publikováno v:
American Journal of Roentgenology. 189:1539-1544
The purpose of this study was to use three analytic methods to measure serum calcium concentration to assess the magnitude and time course of the effects of four gadolinium-based contrast agents.After providing informed consent, 12 healthy adult volu
Publikováno v:
Journal of Magnetic Resonance Imaging. 19:133-140
Purpose To evaluate the safety of OptiMARK® (gadoversetamide injection) administered via power injector. Materials and Methods The study population included 144 healthy volunteers aged 18 years or older randomly assigned to one of seven treatment gr
Autor:
Adams, Michael R. Hynes, Karen P. Galen, James H. Wible, Steven J. Barco, Troup Cm, Jolette K. Wojdyla, MacDonald, Periasamy Mp
Publikováno v:
Investigative Radiology. 36:401-412
RATIONALE AND OBJECTIVES A series of preclinical tests were undertaken during the developmental process to determine the safety profile of gadoversetamide injection (OptiMARK). METHODS Acute intravenous, acute intracisternal, and repeated-dose toxici
Publikováno v:
Journal of Magnetic Resonance Imaging. 7:204-208
A blood-persistent particulate paramagnetic contrast agent has been formulated via size stabilization of manganese-substituted hydroxylapatite by a polyethylene glycol (PEG) bearing a terminal diphosphonate. At high PEG surface densities (35-40 mol%)
Autor:
Kofi Adzamli, Sandeep Nema, Stephen Fallis, Julie A. Beaty-Nosco, Dennis L. Nosco, Jeffrey A. Levine, Max D. Adams, John A. Polta, Richard B. Dorshow, Karen P. Galen, Michael R. Hynes
Publikováno v:
Academic Radiology. 3:S349-S352
Autor:
James H. Wible, Michael R. Hynes
Publikováno v:
Radiology. 233(1)
To measure serum calcium concentration with three different analytic methods after administration of gadoversetamide and three other gadolinium chelates in dogs.Six dogs were injected with 0.1-, 0.3-, 1.0-, and 3.0-mmol/kg doses of gadoversetamide; 1
Publikováno v:
Journal of magnetic resonance imaging : JMRI. 19(1)
To evaluate the safety of OptiMARK (gadoversetamide injection) administered via power injector.The study population included 144 healthy volunteers aged 18 years or older randomly assigned to one of seven treatment groups (N = 20/group). The safety a
Autor:
Michael R. Hynes, Karen P. Galen, John A. Polta, Rebecca A. Wallace, Steven R. Woulfe, Kofi Adzamli, Donald B. Miller, Joe P. Haar
Publikováno v:
Magnetic resonance in medicine. 40(5)
A nonaromatic, small-molecule, gadolinium(3+)-chelate code named MP-2269 was synthesized and evaluated in animals as a potential MR contrast agent for blood pool. The ligand of MP-2269 was prepared by conjugating a lipophilic, albumin-binding moiety,
Autor:
Kofi Adzamli, Steven R. Woulfe, Max D. Adams, John A. Polta, Donald B. Miller, Michael R. Hynes, Joseph P. Haar, Rebecca A. Wallace
Publikováno v:
Academic radiology. 5
The ideal contrast agent for MR angiography should be safe, efficacious, blood-persistent, and easily excreted. The binding of small Gd chelates to macromolecules has been shown to provide a mechanism of proton relaxation enhancement in MR images thr
Publikováno v:
Bioconjugate chemistry. 6(5)
A new series of gadolinium chelates designed as blood pool contrast enhancing agents for magnetic resonance imaging applications is described. Complexes having four Gd(III) chelate units display a significant increase in molecular relaxivity per gado